Skip to main content Skip to search Skip to main navigation

EMA: New Q&A on Third Party Audits in the QP Declaration

EMA has published a Q&A on how to reflect third party audit(s) in part C of the QP declaration.

In part C of the QP declaration, information on audits as basis of QP Declaration of GMP Compliance should be given. Audit(s) of the active substance manufactured at the site(s) listed in PART A should be reported.

The Q&A includes a table where the manufacturing/import authorisation holder (MIAH) site (contract giver) and the audit body (contract acceptor) must be listed.

If the audit is undertaken by the MIAH, the auditing body column should be left empty. If the audit is performed by a third-party body (i.e. contract acceptor on behalf of the MIAH contract giver), this should be detailed as reflected in the contract.

In case the audit is performed on behalf of the MIAH by different entity/entities belonging to the same overall company, this should also be detailed in the auditing body column.

It is emphasised that in case the MIAH site does not perform the audit itself, the MIAH should be the contract giver. Consequently, the contract giver should always correspond to the MIAH site and the contract acceptor is expected to be the auditing body that actually performed the audit.


Source:

EMA: Questions and answers on how should third party audit(s) be reflected in part C of the QP declaration?


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

EMA: New Q&A on Product Lifecycle Management (PLCM)

EMA: New Q&A on Product Lifecycle Management (PLCM)

The EMA has published new Questions & Answers on the use of the Product Lifecycle Management (PLCM) document, clarifying its role within the EU variations framework for post-approval quality changes.
Read more
EMA: New Q&A for Co-Processed Excipients

EMA: New Q&A for Co-Processed Excipients

The EMA has published new Questions & Answers on co-processed excipients (CoPEs) used in solid oral dosage forms, introducing a harmonised, risk-based regulatory approach applicable to human and veterinary medicines.

Read more
What is the Data Lifecycle?

What is the Data Lifecycle?

Here's the answer:
Read more
GMP Regulations Report 2025

GMP Regulations Report 2025

What do the regulatory developments mean for your professional environment? Which requirements have a direct impact on your day-to-day work, and where is there an urgent need for action? Our GMP Regulations Report 2025 provides a clear structure, practical explanations, and the most important regulatory developments of 2025 – concise, well-organized, and relevant.
Read more
EU: Parliament Approves Regulation Proposal on Critical Medicines

EU: Parliament Approves Regulation Proposal on Critical Medicines

The European Parliament has approved regulatory measures aimed at strengthening the availability and supply of critical medicines in the EU.
Read more
What is a gas?

What is a gas?

You can view the answer here:
Read more
Previous
Next